<DOC>
	<DOCNO>NCT00126035</DOCNO>
	<brief_summary>The purpose study assess efficacy Migraid term prevent headache patient migraine typical aura . The secondary objective ass whether Migraid able achieve pain relief and/or relief migraine associate symptom evaluate safety tolerability study treatment .</brief_summary>
	<brief_title>Study With Migraid Device Acute , Early Treatment Migraine With Typical Aura</brief_title>
	<detailed_description>Migraid use aura phase migraine attack duration 60 minute . Reference therapy : No treatment . This mean random patient allocate either two treatment order ; first treatment order use Migraid whenever migraine attack aura occur . During next migraine attack Migraid use vice versa group patient . Patients ask complete diary card record detail two migraine attack severity migraine headache certain point time : = 30 minute , = 60 minute , t= 90 minute , =120 minute , =150 minute , =180 minute = 24 hour . Also , associate symptom ask . Rescue medication data include name , time take amount also register diary card . For primary secondary variable efficacy , follow definition use : Grade score : Pain level : Description 0 : None - No pain ; 1 . Mild - A headache remarkable pain hinder perform usual daily activity ; 2 . Moderate - A headache pain hinders perform usual daily activity , necessitate go bed ; 3 . Severe - A headache pain necessitates go stay bed . The associated symptom grade either present absent . These symptom define conform follow table : Symptom : Description Nausea : Sick stomach/feel like throw ; Vomiting : Throwing puking ; Photophobia : Light bother hurt eye ; Phonophobia : Noise bother hurt ear . A migraine attack define : New onset migraine pain , precede pain-free period least 24-hours duration .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Migraine Aura</mesh_term>
	<criteria>Patients must current history migraine typical aura aura usually follow headache accord International Headache Society ( IHS ) criterion . Patients male female . N.B . When female patient treat migraine attack triptans require precaution safety measure take order prevent pregnancy . Patients age 18 65 year . Patients must experience 14 moderate ( grade 2 ) severe ( grade 3 ) migraine attack per month least two month prior entry study . Patients must willing keep prophylactic drug treatment migraine unchanged . Patients must able distinguish migraine headache headache type ( e.g . tensiontype headache ) onset migraine attack . Patients must able understand complete diary card Patients must willing able give write informed consent prior entry study . Patients must willing able carry Migraid , necessary , apply public place . Migraine patient typical aura without migraine headache thereafter . Patients history suggestive ischaemic heart disease ( IHD ) present evidence ischaemic heart disease ( like angina pectoris , previous myocardial infarction , document silent ischaemia , Prinzmetal 's angina ) , symptoms consistent IHD . Patients suffer coronary vasospasm atherosclerotic disease ( cerebrovascular disease [ CVD ] , peripheral vascular disease [ PVD ] Raynaud ’ disease ) place increase risk coronary ischaemia . Patients history cerebrovascular accident ( CVA ) transient ischaemic attack ( TIA ) . Patients supine diastolic blood pressure &gt; 95 mm Hg and/or systolic blood pressure &gt; 160 mm Hg ( treat untreated ) Visit 1 . Patients history epilepsy structural brain lesion low convulsion threshold . Patients tensiontype headache &gt; 15 days/month either two month prior study . Current abuse opioid analgesic psychotropic drug . History ( within past year ) current abuse ergotamine ( abuse define &gt; 10 mg/week ) . Current abuse alcohol ( accord local recommendation ) drug . Patients suffer severe concurrent medical condition may affect interpretation efficacy safety data otherwise contraindicate participation clinical study . Patients history ophthalmoplegic , basilar hemiplegic migraine . Patients history impaired hepatic renal function . Patients participate clinical trial within previous 3 month plan participate another clinical research study time study . Patients concurrent medical psychiatric condition , investigator ’ opinion , may affect interpretation efficacy safety data otherwise contraindicate participation clinical trial . Patients participate investigator , study coordinator , employee investigator , family member aforementioned .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>Acute Migraine</keyword>
	<keyword>Device</keyword>
	<keyword>Migraid</keyword>
	<keyword>Treatment</keyword>
	<keyword>Aura</keyword>
</DOC>